NanoEntek is showing strong performance.
As of 9:06 AM on the 14th, NanoEntek is trading on the KOSDAQ market at 4,035 KRW, up 790 KRW (24.35%) from the previous day.
On the same day, NanoEntek announced that it will conduct a third-party paid-in capital increase worth 17.5 billion KRW targeting Aplus Asset Advisors.
The company is a manufacturer and seller of point-of-care testing (POCT) medical devices and biotechnology research equipment based on lab-on-a-chip technology.
It has formed partnerships with Thermo Fisher Scientific and PerkinElmer in the United States to supply biotechnology research equipment products through contract manufacturing.
In 2023, the in vitro diagnostics division launched the ADAM-rWBC HT (high-throughput automated white blood cell counter) based on proven technology, expanding coverage in U.S. blood banks and entering the European market.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
